Kilitch Drugs(India)
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Kilitch Drugs (India) board approved the sale of its entire shareholding in Kilitch Estro Biotech PLC to HarmeeCare Pharmaceuticals, a state-owned enterprise of Ethiopia's Oromia Regional State, for aggregate consideration of USD 14 million, of which USD 12.86 million was due to the company. The board also approved conversion of up to Rs 57 crore of outstanding debt owed by the subsidiary into equity prior to completion and appointed Dr Milind Kishor Madhani and Gautam Rajan as additional independent directors. Binding minutes recording the key terms were signed on 22 October 2026, with the share purchase agreement to follow and completion scheduled for 31 January 2027 subject to shareholder approval. Kilitch Estro Biotech operated a cephalosporin manufacturing plant in Ethiopia that reported turnover of Rs 47.57 crore in 2025-26 and had net worth of minus Rs 8.43 crore at the end of March. The plant opened in July 2021 after about Rs 50 crore of capital expenditure and ran at 5-7% utilisation on private sales before winning its first government tender worth $9.13 million in 2023-24. The Ethiopian business reported a loss of Rs 2.02 crore in 2025-26, while the foreign subsidiary posted a Rs 2.87 crore loss on Rs 3.97 crore of revenue in the June quarter. Consolidated revenue was Rs 235.47 crore in the year to March, with capital work in progress of Rs 140.02 crore at the Pen sterile campus.
Powered by Tijori
Kilitch Drugs (India) board approved the sale of its entire shareholding in Kilitch Estro Biotech PLC to HarmeeCare Pharmaceuticals, a state-owned enterprise of Ethiopia's Oromia Regional State, for aggregate consideration of USD 14 million, of which USD 12.86 million was due to the company. The board also approved conversion of up to Rs 57 crore of outstanding debt owed by the subsidiary into equity prior to completion and appointed Dr Milind Kishor Madhani and Gautam Rajan as additional independent directors. Binding minutes recording the key terms were signed on 22 October 2026, with the share purchase agreement to follow and completion scheduled for 31 January 2027 subject to shareholder approval. Kilitch Estro Biotech operated a cephalosporin manufacturing plant in Ethiopia that reported turnover of Rs 47.57 crore in 2025-26 and had net worth of minus Rs 8.43 crore at the end of March. The plant opened in July 2021 after about Rs 50 crore of capital expenditure and ran at 5-7% utilisation on private sales before winning its first government tender worth $9.13 million in 2023-24. The Ethiopian business reported a loss of Rs 2.02 crore in 2025-26, while the foreign subsidiary posted a Rs 2.87 crore loss on Rs 3.97 crore of revenue in the June quarter. Consolidated revenue was Rs 235.47 crore in the year to March, with capital work in progress of Rs 140.02 crore at the Pen sterile campus.
Powered by Tijori
Feb 11 (Reuters) - Kilitch Drugs (India) Ltd KIDI.NS:
KILITCH DRUGS (INDIA) LTD - TO ISSUE BONUS SHARES IN RATIO OF 1:1
Source text: ID:nBSE9XytTD
Further company coverage: KIDI.NS
(([email protected];))
Feb 11 (Reuters) - Kilitch Drugs (India) Ltd KIDI.NS:
KILITCH DRUGS (INDIA) LTD - TO ISSUE BONUS SHARES IN RATIO OF 1:1
Source text: ID:nBSE9XytTD
Further company coverage: KIDI.NS
(([email protected];))
July 2 (Reuters) - Kilitch Drugs (India) Ltd KIDI.NS:
KILITCH DRUGS (INDIA) LTD - TO RAISE UP TO 500 MILLION RUPEES VIA RIGHTS ISSUE
KILITCH DRUGS (INDIA) LTD - PROCEEDS TO FUND GREENFIELD PROJECT IN MAHARASHTRA
Source text: ID:nBSE4s6k5x
Further company coverage: KIDI.NS
(([email protected];;))
July 2 (Reuters) - Kilitch Drugs (India) Ltd KIDI.NS:
KILITCH DRUGS (INDIA) LTD - TO RAISE UP TO 500 MILLION RUPEES VIA RIGHTS ISSUE
KILITCH DRUGS (INDIA) LTD - PROCEEDS TO FUND GREENFIELD PROJECT IN MAHARASHTRA
Source text: ID:nBSE4s6k5x
Further company coverage: KIDI.NS
(([email protected];;))
Feb 23 (Reuters) - Kilitch Drugs (India) Ltd KIDI.NS:
UNIT WON TENDER ISSUED BY FEDERAL DEMOCRATIC REPUBLIC OF ETHIOPIA PHARMACEUTICAL SUPPLY SERVICE
UNIT WON TENDER FOR SUPPLY OF PHARMACEUTICALS
CONTRACT FOR $9.1 MILLION
Source text for Eikon: ID:nBSE3FQc2b
Further company coverage: KIDI.NS
(([email protected];))
Feb 23 (Reuters) - Kilitch Drugs (India) Ltd KIDI.NS:
UNIT WON TENDER ISSUED BY FEDERAL DEMOCRATIC REPUBLIC OF ETHIOPIA PHARMACEUTICAL SUPPLY SERVICE
UNIT WON TENDER FOR SUPPLY OF PHARMACEUTICALS
CONTRACT FOR $9.1 MILLION
Source text for Eikon: ID:nBSE3FQc2b
Further company coverage: KIDI.NS
(([email protected];))
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Kilitch Drugs(India) do?
Kilitch Drugs (India) Limited, based in Mumbai, is a pharmaceutical company focusing on manufacturing and marketing antibacterial parenteral formulations including Carbapenems, Cephalosporins, and anti malarials. It transferred some products to Akorn India Pvt. Ltd. in 2012.
Who are the competitors of Kilitch Drugs(India)?
Kilitch Drugs(India) major competitors are Zim Laboratories, Wanbury, Anuh Pharma, Trident Lifeline, Shivalik Rasayan, Prevest Denpro, Albert David. Market Cap of Kilitch Drugs(India) is ₹703 Crs. While the median market cap of its peers are ₹490 Crs.
Is Kilitch Drugs(India) financially stable compared to its competitors?
Kilitch Drugs(India) seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Kilitch Drugs(India) pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Kilitch Drugs(India) latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Kilitch Drugs(India) allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress
How strong is Kilitch Drugs(India) balance sheet?
Balance sheet of Kilitch Drugs(India) is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Kilitch Drugs(India) improving?
The profit is oscillating. The profit of Kilitch Drugs(India) is ₹29.2 Crs for TTM, ₹30.17 Crs for Mar 2026 and ₹26.7 Crs for Mar 2025.
Is the debt of Kilitch Drugs(India) increasing or decreasing?
Yes, The net debt of Kilitch Drugs(India) is increasing. Latest net debt of Kilitch Drugs(India) is ₹55.19 Crs as of Mar-26. This is greater than Mar-25 when it was ₹29.78 Crs.
Is Kilitch Drugs(India) stock expensive?
Kilitch Drugs(India) is not expensive. Latest PE of Kilitch Drugs(India) is 23.38, while 3 year average PE is 31.11. Also latest EV/EBITDA of Kilitch Drugs(India) is 21.37 while 3yr average is 22.48.
Has the share price of Kilitch Drugs(India) grown faster than its competition?
Kilitch Drugs(India) has given better returns compared to its competitors. Kilitch Drugs(India) has grown at ~28.86% over the last 4yrs while peers have grown at a median rate of 12.96%
Is the promoter bullish about Kilitch Drugs(India)?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Kilitch Drugs(India) is 63.77% and last quarter promoter holding is 63.77%.
Are mutual funds buying/selling Kilitch Drugs(India)?
There is Insufficient data to gauge this.